
Mesothelioma - Pipeline Insight, 2024
Description
Mesothelioma - Pipeline Insight, 2024
DelveInsight’s, “Mesothelioma - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Mesothelioma: Overview
Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 – 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue. Any amount of asbestos exposure can cause mesothelioma. However, certain occupations may experience higher rates of exposure. There are four main types of mesothelioma based on tumor location. The most common type is malignant pleural mesothelioma. The pattern of nodal metastases is different from that seen in lung cancer. With malignant pleural mesothelioma, there is a direct local invasion of the lymph nodes. Overall, the involvement of lymph nodes in malignant pleural mesothelioma is not common.
The three types of mesothelioma based on the cell type are epithelioid, sarcomatoid, and mixed. The epithelioid type is associated with better outcomes. The tumor is often multifocal, forming multiple nodules starting with the parietal pleura. Spread occurs locally in the visceral pleura before extending to the chest wall, diaphragm, or mediastinum. Regional lymph node spread begins with the bronchopulmonary or hilar lymph nodes before moving to the carinal, internal mammary or peridiaphragmatic nodes.
After recognizing symptoms, doctors will perform a variety of tests and procedures to confirm a mesothelioma diagnosis. The doctor may then conduct a physical exam to check for any lumps or abnormalities. They may then conduct basic imaging tests, like an X-ray, and blood work. Doctors use basic blood to check a patient’s overall health and organ function. Biopsies are the only way to definitively diagnose mesothelioma.
Treatment for mesothelioma cancer typically involves a combination of therapies. Patients may receive mesothelioma drugs, radiation or surgery. Doctors will determine an individual’s treatment plan based on cancer type, stage and patient characteristics. Researchers are continuously making advancements in mesothelioma treatment. In medical studies called clinical trials, doctors test the safety and efficacy of emerging drugs and treatments. Experimental therapies may be an option for patients who are not responding to traditional types of treatment.
""Mesothelioma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mesothelioma pipeline landscape is provided which includes the disease overview and Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Mesothelioma.
This segment of the Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mesothelioma Emerging Drugs
- TR002: Trizell
- MTG201: Momotaro-Gene
The Phase II trial (NCT04013334), which is being conducted at the Baylor College of Medicine in Houston, Texas, is an open-label, single-arm study designed to assess the efficacy, safety and tolerability of intratumoral administration of MTG201 in combination with nivolumab. The trial will enroll up to twelve patients with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy.
- PM8002: Biotheus
- MT-8421: Molecular Templates
Further product details are provided in the report……..
Mesothelioma: Therapeutic Assessment
This segment of the report provides insights about the different Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Mesothelioma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Mesothelioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mesothelioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mesothelioma drugs.
Mesothelioma Report Insights
- Mesothelioma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mesothelioma drugs?
- How many Mesothelioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mesothelioma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mesothelioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mesothelioma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Molecilar Templates
- Trizell
- Momotaro-Gene
- Biotheus
- Lubris Biopharma
- Amphera
- Momotaro-Gene Inc.
- Kissei Pharmaceutical Co., Ltd.
- Novartis Pharmaceuticals
- Oncovir, Inc.
- Sumitomo Dainippon Pharma Oncology
- Bayer
- Hutchison Medipharma Limited
- Targovax
- Polaris Group
- Epizyme, Inc.
- Sanofi
- AstraZeneca
- Vivace Therapeutics, Inc
- Ascentage Pharma Group Inc.
- Shionogi
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Seagen Inc.
- Eli Lilly and Company
- Incyte Corporation
- MT-8421
- TR002
- MTG201
- PM8002
- MesoPher
- MTG201
- YS110
- IAG933
- Poly-ICLC
- BBI608
- Anetumab ravtansine
- CPI-0209
- XmAb20717
- HMPL-453
- INBRX-109
- SO-C101
- VMD-928 300
- NGM707
- ONCOS-102
- iCasp9M28z
- Niraparib
- ADI-PEG 20
- VT3989
Table of Contents
210 Pages
- Introduction
- Executive Summary
- Mesothelioma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Mesothelioma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Mesothelioma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Mesothelioma Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- TR002: Trizell
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MTG201: Momotaro-Gene
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MT-8421: Molecular Templates
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Mesothelioma Key Companies
- Mesothelioma Key Products
- Mesothelioma- Unmet Needs
- Mesothelioma- Market Drivers and Barriers
- Mesothelioma- Future Perspectives and Conclusion
- Mesothelioma Analyst Views
- Mesothelioma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.